Somewhat Critical News Coverage Somewhat Unlikely to Affect ContraFect (CFRX) Stock Price
Media headlines about ContraFect (NASDAQ:CFRX) have trended somewhat negative on Sunday, according to Accern Sentiment. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ContraFect earned a news sentiment score of -0.01 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.7633731141712 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Brokerages Set $3.96 Target Price for ContraFect Corp (CFRX) (americanbankingnews.com)
- ContraFect (CFRX) Releases Quarterly Earnings Results, Misses Estimates By $0.17 EPS (americanbankingnews.com)
- ContraFect Announces Second Quarter 2018 Financial Results (finance.yahoo.com)
- ContraFect: 2Q Earnings Snapshot (finance.yahoo.com)
- Q3 2018 Earnings Forecast for ContraFect Corp Issued By Piper Jaffray Companies (CFRX) (americanbankingnews.com)
ContraFect traded up $0.11, reaching $2.03, during midday trading on Friday, MarketBeat Ratings reports. The stock had a trading volume of 126,114 shares, compared to its average volume of 234,047. ContraFect has a 12 month low of $0.80 and a 12 month high of $2.93. The firm has a market capitalization of $141.43 million, a price-to-earnings ratio of -5.49 and a beta of -0.51.
CFRX has been the topic of a number of recent analyst reports. LADENBURG THALM/SH SH initiated coverage on ContraFect in a research note on Tuesday, July 10th. They issued a “buy” rating on the stock. Janney Montgomery Scott initiated coverage on ContraFect in a research note on Thursday, June 28th. They issued a “buy” rating on the stock. Chardan Capital initiated coverage on ContraFect in a research report on Friday, June 15th. They issued a “buy” rating and a $2.80 target price for the company. Finally, ValuEngine raised ContraFect from a “sell” rating to a “hold” rating in a research report on Friday, June 1st.
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
See Also: Stock Symbols and CUSIP Explained
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.